ArticleThe Journal of infectious diseases2019
An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Efficacy of Pam3CSK4 as a cross-species adjuvant for polysaccharide vaccines in humanized mouse and non-human primate models.Nature communications · 2026Article
- Recent developments of vaccines for older adults: Adjuvants and beyond.Human vaccines & immunotherapeutics · 2025Review
- Pam3CSK4 as a Cross-Species Adjuvant for Polysaccharide Vaccines: Efficacy in Humanized Mouse and Non-Human Primate Models.bioRxiv : the preprint server for biology · 2025Article
- B cell-expressed CD1d promotes MPL/TDCM lipid emulsion adjuvant effects in polysaccharide vaccines.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Distinct effects of adjuvants on B cell responses to protein or polysaccharide antigens contained in glycoconjugate vaccines.Frontiers in immunology · 2025Article
- Review
- TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity.ImmunoHorizons · 2024Article
- A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.Frontiers in immunology · 2024Article
- Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.Immunity & ageing : I & A · 2021Review
- An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.Pharmaceutics · 2021Review
- B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- A TLR4-TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells.Cancer immunology, immunotherapy : CII · 2020Article
- Influence of immune aging on vaccine responses.The Journal of allergy and clinical immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Protection against encapsulated bacteria can be elicited using polysaccharide vaccines. These antigens often behave as T-cell-independent type 2 antigens (TI-2 Ags). However, TI-2 Ags, including pneumococcal polysaccharides, often elicit weak immunoglobulin G (IgG) responses and are refractive to boosting. Conjugate vaccines have not completely overcome this challenge and hence, alternative strategies are required to enhance polysaccharide vaccine responses. Herein, we describe an adjuvant consisting of a Toll-like receptor and C-type lectin receptor agonist pairing that significantly increases primary immunoglobulin M and IgG responses to TI-2 Ags as well as enables significant boosting when coadministered with polysaccharide vaccines. Consistent with this, the adjuvant significantly increased the generation of both TI-2 memory B cells and long-lived antibody secreting cells. Adjuvant effects were highly dependent on B-cell-intrinsic MyD88, but not Trif expression. Importantly, coadministration of the adjuvant with the Pneumovax vaccine significantly increased the protective efficacy of vaccination in a lethal challenge mouse model of pneumococcal respiratory infection. Collectively, these data provide evidence that B-cell-directed adjuvants have promise in significantly improving the quality and quantity of serologic and B-cell memory responses to clinically relevant polysaccharide vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.